ArticleClinical epigenetics2026
DNMT inhibitor ameliorates hyperglycemia and renal inflammation partially via reversing hypermethylation-induced Klotho suppression in diabetic mice.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIn diabetic kidney disease (DKD), DNA hypermethylation-mediated silencing of protective genes constitutes a key mechanism of metabolic memory, driving persistent renal injury. Klotho suppression critically exacerbates renal inflammation and injury. Our preliminary studies documented Klotho promoter hypermethylation in DKD kidneys. However, direct evidence linking its sustained downregulation to this epigenetic aberration and demethylation’s therapeutic benefits remains unestablished. This study investigates whether demethylation treatment-mediated reversal of Klotho promoter hypermethylation restores its expression to alleviate renal inflammation and injury in DKD.
methodsDiabetic db/db mice and age-matched wild-type controls were used. At 8 weeks, db/db mice received intraperitoneal injections of the DNA methyltransferase (DNMT) inhibitor 5-Azacytidine (5-Aza) or phosphate-buffered saline (PBS) three times weekly. After 12 weeks, samples were collected for analysis. HK-2 cells were utilized for in vitro validation.
resultsDemethylation treatment with 5-Aza reduced Klotho promoter hypermethylation and upregulated Klotho expression in db/db mouse kidneys and HK-2 cells. 5-Aza dose-dependently reduced fasting blood glucose by up to 72%, proteinuria, and serum creatinine levels, while improving renal pathology (glomerular hypertrophy, mesangial expansion, basement membrane thickening, podocyte injury). RNA sequencing demonstrated suppression of multiple inflammatory signaling pathways in kidneys of 5-Aza-treated db/db mice. Furthermore, 5-Aza substantially attenuated renal macrophage infiltration and inflammasome activation in db/db mice, concurrently reducing systemic inflammation and improving insulin resistance.
conclusionsOur study demonstrates that DNA hypermethylation drives Klotho downregulation in DKD. DNMT inhibitor alleviates hyperglycemia, renal inflammation and injury in db/db mice by reversing hypermethylation-mediated Klotho suppression. Targeting aberrant DNA methylation represents a novel therapeutic strategy for DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.